adrenomedullin (22-52)
PeptideexperimentalImaging agent
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02216279)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Adrenomedullin receptor AM1; CALCRL/RAMP2 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Imaging
- 99-MTC
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068569 ↗
Also known as
- adrenomedullin (22-52)
- adrenomedullin (22-52), glycyl-glycyl-alanyl-glycyl-cysteinyl-(peg)4-cysteinyl-
- adrenomedullin (22-52), gly-gly-ala-gly-cys-(peg)4-cys-
- gly-gly-d-ala-gly-cys-d-(peg)4-cys-ham(22-52)
- pulmobind
- pulmobind
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07059546 | N/A | Aug 1, 2025 | University of Copenhagen |
| NCT06072118 | Phase 2 | Jan 6, 2022 | National Cerebral and Cardiovascular Center |
| NCT04460963 | N/A | Oct 31, 2020 | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| NCT04417036 | Phase 2 | Aug 31, 2020 | Bayer |
| NCT04111484 | N/A | Sep 28, 2018 | University of Copenhagen |
| NCT02216279 | Phase 2 | Sep 1, 2014 | University of Montreal |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Bayer | For profit | 1 | 1 | 1 | 2020 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cerebral and Cardiovascular Center | Government | 1 | 1 | 1 | 2022 |
| University of Montreal | Academic/Hospital | 1 | 1 | 1 | 2014 |
5 organizations
Page 1 / 1